OptiNose, Inc. provided preliminary unaudited earnings guidance for the three-month period ended March 31, 2024. For the period, the company expects to report approximately $14.9 million in net revenue from sales of XHANCE; a loss from operations of approximately $8.1 million; and a net loss of approximately $14.1 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.11 USD | -1.77% | -11.90% | -13.95% |
May. 14 | Transcript : OptiNose, Inc., Q1 2024 Earnings Call, May 14, 2024 | |
May. 14 | Earnings Flash (OPTN) OPTINOSE Posts Q1 Revenue $14.9M, vs. Street Est of $13.7M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.95% | 161M | |
+38.51% | 727B | |
+33.05% | 599B | |
-6.23% | 354B | |
+18.78% | 328B | |
+1.35% | 277B | |
+16.00% | 243B | |
+8.09% | 205B | |
-5.77% | 203B | |
+6.19% | 164B |
- Stock Market
- Equities
- OPTN Stock
- News OptiNose, Inc.
- OptiNose, Inc. Provides Preliminary Unaudited Earnings Guidance for the Three-Month Period Ended March 31, 2024